Supernus Pharmaceuticals
SUPN
#5357
Rank
NZ$2.85 B
Marketcap
NZ$49.01
Share price
5.58%
Change (1 day)
-39.25%
Change (1 year)

Earnings for Supernus Pharmaceuticals (SUPN)

Earnings in 2026 (TTM): -NZ$0.21 Billion

According to Supernus Pharmaceuticals 's latest financial reports the company's current earnings are NZ$0.83 Billion. In 2025 the company made an earning of -NZ$78.97 Million a decrease over its 2024 earnings that were of NZ$0.14 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Supernus Pharmaceuticals from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -NZ$0.21 Billion164.52%
2025 -NZ$78.97 Million-155.5%
2024 NZ$0.14 B1446.62%
2023 NZ$9.19 M-92.36%
2022 NZ$0.12 B-29.8%
2021 NZ$0.17 B-49.79%
2020 NZ$0.34 B12.99%
2019 NZ$0.30 B7.58%
2018 NZ$0.28 B54.9%
2017 NZ$0.18 B84.25%
2016 NZ$98.4 M202.27%
2015 NZ$32.55 M-462.04%
2014 -NZ$9 Million-94%
2013 -NZ$0.15 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
NZ$33.21 B-15,720.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
NZ$14.43 B-6,889.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$61.69 B-29,110.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$20.10 B-9,555.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Zogenix
ZGNX
-NZ$0.38 Billion 76.92%๐Ÿ‡บ๐Ÿ‡ธ USA
United Therapeutics
UTHR
NZ$2.81 B-1,422.50%๐Ÿ‡บ๐Ÿ‡ธ USA